Volume 5, Issue 1, January 2017, Page: 6-9
Aripiprazol Versus Quetiapine in Treatment of Non-affective Acute Psychosis: A Double-Blind, Randomized - Controlled Clinical Trial
S. Mohamad Moosavi, Department of Psychiatry, Mazandaran University of Medical Sciences, Sari, Iran
Mahshid Ahmadi, Department of Social Medicine, Mazadaran University of Medical Sciences, Sari, Iran
Mani B. Monajemi, School of Psychology and Mental Health Sciences, University of Tehran, Tehran, Iran
Received: Jul. 24, 2016;       Accepted: Dec. 14, 2016;       Published: Feb. 21, 2017
DOI: 10.11648/j.ajpn.20170501.12      View  2813      Downloads  93
Abstract
Objective: The primary objective of this study was to assess the efficacy of Quetiapine versus Aripiprazol in treating non-affective acute psychosis. Methods: This study is double blind, randomized-controlled clinical trial (RCT). A total number of 90 hospitalized patients with the diagnosis of acute psychosis were selected. The patients were treated with Quetiapine (mean: 500 mg/day) or Aripiprazol (mean: 20 mg/day), in a 4 weeks period. The positive and negative symptoms scale (PANSS) and clinical global impression severity scale (CGIS-s) were used in the first and the last day of trial. Results: This study reveals that both of these drugs can substantially reduce the severity of symptoms in acute psychosis. Aripiprazol reduced positive symptoms and general symptoms scores and total scores more than Quetiapine. Differences in reducing negative scores were not significant and both drugs had the same therapeutic effect. In this sense, there was no difference in reducing negative symptoms in acute psychosis between Aripiprazol and Quetiapine. Conclusion: According to some differences with similar studies, study on larger sample pool and in longer period in future researches can be advised.
Keywords
Antipsychotics, Aripiprazol, Quetiapine, Non-affective Acute Psychosis
To cite this article
S. Mohamad Moosavi, Mahshid Ahmadi, Mani B. Monajemi, Aripiprazol Versus Quetiapine in Treatment of Non-affective Acute Psychosis: A Double-Blind, Randomized - Controlled Clinical Trial, American Journal of Psychiatry and Neuroscience. Vol. 5, No. 1, 2017, pp. 6-9. doi: 10.11648/j.ajpn.20170501.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
J. Sadock B: Signs and symptoms in psychiatry. Kaplan &Sadock's Comprehensive Textbook of Psychiatry 9th Edition 927.
[2]
Kane JM, Stroup TS, Marder SR: Schizophrenia: Pharmacological Treatment. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 9th Edition: 1547.
[3]
Kane JM, Stroup TS, Marder SR: Schizophrenia: Pharmacological Treatment. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 9th Edition: 1548.
[4]
Kane JM, Stroup TS, Marder SR: Schizophrenia: Pharmacological Treatment. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 9th Edition: 1549.
[5]
Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP et al: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007, 164(3): 428-436.
[6]
Ghamari Givi H, Molavi C, Heshmati R, 2010. Examine the factor structure of the scale of positive and negative symptoms of schizophrenia spectrum disorders. Journal of Clinical, Psychology. 2: 1-10.
[7]
Marder SR, Hurford IM, KammenDPv: Second-Generation Antipsychotics. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 9th Edition: 3236 table: 3231.3228.
[8]
Missio G, Moreno DH, Fernandes F, Bio DS, Soeiro-de-Souza MG, Rodrigues dos Santos D Jr, David DP, Costa LF, Demétrio FN, Moreno RA.. (2013). The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole.. Available: http://www.ncbi.nlm.nih.gov/pubmed/23805994. Last accessed 28/02/2016. doi: 10.1186/1745-6215-14-190.
[9]
Jin H1, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV. (2013). Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.. Available: http://www.ncbi.nlm.nih.gov/pubmed/23218100. Last accessed 28/02/2016. doi: 10.4088/JCP.12m08001.
[10]
BMC Psychiatry. 2012 Aug 2; 12: 99. doi: 10.1186/1471-244X-12-99. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospitaldischarge: a retrospective cohort study. Berger A(1), Edelsberg J, Sanders KN, Alvir JM, Mychaskiw MA, Oster G. PMCID: PMC3480886, PMID: 22856540 [PubMed - indexed for MEDLINE]
[11]
Stroup TS1, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (C. Available: http://www.ncbi.nlm.nih.gov/pubmed/21768610. Last accessed 28/02/2016. doi: 10.1176/appi.ajp.2011.10111609.
[12]
Schizophr Bull. 2012 Jun; 38 (4): 845-53. doi: 10.1093/schbul/sbq172. Epub 2011 Feb, Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Olfson M (1), Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. PMCID: PMC3406514PMID: 21307041 [PubMed - indexed for MEDLINE].
Browse journals by subject